Ischemia-reperfusion injury of the appendicular musculoskeletal system

New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023

Retrieved on: 
Wednesday, April 26, 2023
Mont Blanc, NCX, Retina, Glaucoma, Erosion (morphology), ARVO, IOP, Nitric oxide, PDE5, Ischemia-reperfusion injury of the appendicular musculoskeletal system, NDA, Ocular hypertension, Euronext Paris, NO, HIV disease progression rates, Patient, Sickle cell retinopathy, Annual general meeting, Rabbit, Association for Research in Vision and Ophthalmology, Research, COX, Safety, Telescopic sight, Pharmaceutical industry, Ophthalmology, New Data Seal

New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023

Key Points: 
  • New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023
    Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that studies highlighting nonclinical data on NCX 470 and NCX 1728 have been presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023 being held April 23-27, 2023 in New Orleans, LA, United States.
  • Effectively managing the ocular blood flow may slow the progressive worsening of retinal cell function seen in glaucoma patients.
  • This work shows compelling new evidence of retinal cell protective activity with NCX 470 in addition to its IOP lowering ability.
  • Specifically, NCX 470 is found to reverse both hemodynamic and retinal cell impairments consequent to ET-1 induced ischemia/reperfusion injury in rabbits.

Nicox to Present at Upcoming Scientific Conferences

Retrieved on: 
Friday, March 3, 2023
Mont Blanc, Safety, Glaucoma, Annual general meeting, AGS, American Glaucoma Society, Nitric oxide, Ischemia-reperfusion injury of the appendicular musculoskeletal system, Association for Research in Vision and Ophthalmology, Intraocular pressure, Patient, Research, Rabbit, Retina, PDE5, Erosion (morphology), COX, IOP, NO, NCX, Denali, Euronext Paris, State University of New York Upstate Medical University, Ocular hypertension, ARVO, Pharmaceutical industry, Clothing, Telescopic sight, Ophthalmology, Latanoprost

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced a number of presentations at key ophthalmology conferences including the American Glaucoma Society (AGS) Annual Meeting 2023 and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced a number of presentations at key ophthalmology conferences including the American Glaucoma Society (AGS) Annual Meeting 2023 and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023.
  • The first randomized, double-masked, multi-center, parallel group trial conducted in the United States (Mont Blanc) comparing NCX 470 (0.1%) to latanoprost (0.005%) was completed in October 2022.
  • The second Phase 3 trial Denali, similarly designed to Mont Blanc, and which includes a long-term safety extension, is ongoing.
  • NCX 1728 is an NO-donating phosphodiasterase type-5 (PDE5) inhibitor under preclinical evaluation for development in retinal conditions.

PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

Retrieved on: 
Thursday, December 15, 2022
Complex regional pain syndrome, Status epilepticus, Liver, Neurological disorder, Emergency, Life expectancy, Diagnosis, Disorder, Quality of life, Mortality, Reperfusion, Incidence, Ischemia, Kidney, Food, Marketing, FDA, Ischemia-reperfusion injury of the appendicular musculoskeletal system, Organ transplantation, Neuromuscular disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Seizure, Amyotrophic lateral sclerosis, Heart, Ischemic preconditioning, CSE, IL-6, Disease, Orphan drug, Orphan Drug Act of 1983, Transplant, Lung, OTCQB, IRI, Red blood cell, Injury, Rett syndrome, Patient, Mental health, Pharmaceutical industry, Dentistry, Vaccine, Ketamine

TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation.

Key Points: 
  • TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation.
  • Fabio Chianelli, CEO of PharmaTher, commented: “This is our fourth orphan drug designation granted by the FDA for ketamine.
  • Organ Procurement and Transplantation Network, there were 41,355 solid organ transplantations in 2021, and thus far in 2022, there has been 39,241 solid organ transplantation with approximately 105,000 patients waiting for solid organ transplants in the United States.
  • The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor.

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)

Retrieved on: 
Wednesday, September 7, 2022
ADME, Literature, Enzyme, IgG4-related ophthalmic disease, Acute kidney injury, Vance DeGeneres, University, Kidney, Potassium, Safety, Hepatic encephalopathy, Research, Therapy, AKI, Chronic kidney disease, Randomized controlled trial, Hyperphosphatemia, Decision-making, Degenerative disease, Ischemia-reperfusion injury of the appendicular musculoskeletal system, MG, Macular degeneration, KATP, LOS, Kidney disease, RATS, Patent, Alcoholic hepatitis, Liver disease, Animal, GLOBE, Pharmacology, Urine, Nasdaq, Company, Biotechnology, ATP, Nicorandil, AMD, Ischemia, Oxidative stress, Patient, Pharmaceutical industry, Medicine, SUR2B

LOS ALTOS, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced key findings of UNI-494 efficacy from a preclinical study in rodent model of Acute Kidney Injury.

Key Points: 
  • LOS ALTOS, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced key findings of UNI-494 efficacy from a preclinical study in rodent model of Acute Kidney Injury.
  • The Company evaluated the effect of UNI-494 on ischemia-reperfusion induced acute kidney injury (IR-AKI) in rats.
  • We are excited to report this key finding from the IR-AKI model showing treatment with UNI-494 significantly reduced this key biomarker of kidney injury that is a well-accepted biomarker of proximal renal tubule damage.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.For more information, please visit www.unicycive.com .

AM-Pharma Announces Publication of In Vivo Acute Kidney Injury Study Demonstrating Ilofotase Alfa’s Dual Protective Mechanism

Retrieved on: 
Tuesday, July 5, 2022
Health, Surgery, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Mouse, LPS, Death, A2A, Sepsis, Patient, III, Damage-associated molecular pattern, Reperfusion, RATS, Ischemia-reperfusion injury of the appendicular musculoskeletal system, Alkaline phosphatase, AKI, Acute kidney injury, Inflammation, Kidney, ADP, Therapy, Homeostasis, ATP, Doctor of Philosophy, Pathogen-associated molecular pattern, Research, MD, Coagulation, Ischemia, Adenosine, Pharmaceutical industry

The study shows that ilofotase alfa protects the kidney through the activation of adenosine receptors in both rats and mice following ischemia reperfusion induced AKI.

Key Points: 
  • The study shows that ilofotase alfa protects the kidney through the activation of adenosine receptors in both rats and mice following ischemia reperfusion induced AKI.
  • The 1000 U/Kg dose tested in this study is, comparable to the dose currently being tested in the global phase III pivotal study of ilofotase alfa for the treatment of sepsis-associated acute kidney injury (SA-AKI).
  • We are very encouraged by the findings of this study, as these data further validate the role of ilofotase alfa in protecting the kidney during episodes of acute kidney injury, said Maarten Kraan, MD, PhD, Chief Medical Officer of AM-Pharma.
  • Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year.

Nicox at ARVO 2022: Presentation of clinical Phase 2 results on NCX 4251 and new non-clinical evidence of improved hemodynamic and retinal cell physiology on NCX 470

Retrieved on: 
Monday, May 2, 2022
Mont Blanc, Kepler, Bausch & Lomb, Laborie (company), Johannes Kepler, Euronext Paris, Allergic conjunctivitis, Denali, Association, LLC, Patient, Research, Annual general meeting, Therapy, Ischemia-reperfusion injury of the appendicular musculoskeletal system, Glaucoma, Intraocular pressure, Nitric oxide, Duane syndrome, CO, Association for Research in Vision and Ophthalmology, NO, Rabbit, University, NCX, COX, IOP, Primate, ARVO, Ocular hypertension, Fluticasone, Compartment, Pharmaceutical industry, Ophthalmology

NCX 4251 is a novel and patented ophthalmic suspension of fluticasone propionate nanocrystals currently in Phase 2 development in the U.S. for patients with dry eye disease.

Key Points: 
  • NCX 4251 is a novel and patented ophthalmic suspension of fluticasone propionate nanocrystals currently in Phase 2 development in the U.S. for patients with dry eye disease.
  • Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.
  • Nicoxs lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
  • Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury

Retrieved on: 
Thursday, February 3, 2022
Safety, Forward-looking statement, Risk, Patient, Hospital, Publication, SEDAR, University, AKI, Lung, Dialysis, COVID-19, Kidney transplantation, Liver, Cell, Human, Conversation, CAD, Exercise, Ferroptosis, Inflammation, Acute kidney injury, Teaching hospital, Chronic kidney disease, II, Peptide, Red blood cell, Glutathione, OTCQB, CATCO, Cilastatin, Reperfusion, Disease, Company, Endothelium, GLOBE, News, Kidney, Science Advances, Ischemia-reperfusion injury of the appendicular musculoskeletal system, Therapy, Science, Lead, Technische Universität Darmstadt, Cell death, Ischemia, Blockchain.com, Pharmaceutical industry, Risk management

inflammation) to the kidney following ischemia reperfusion injury, which is injury that occurs after a reduction in blood flow to the kidney.

Key Points: 
  • inflammation) to the kidney following ischemia reperfusion injury, which is injury that occurs after a reduction in blood flow to the kidney.
  • Ischemia reperfusion injury is a common cause of AKI in humans undergoing cardiac surgery or kidney transplantation.
  • Importantly, the study also confirmed the mechanism of action of two DPEP-1 inhibitors, the LSALT peptide (Metablok) and cilastatin that effectively protected the kidney during ischemia reperfusion injury.
  • Both the LSALT peptide and cilastatin are protected by composition and method of use patents for AKI respectively and held by Arch Biopartners.

XBiotech to Launch Novel Candidate Therapy for Stroke

Retrieved on: 
Thursday, October 28, 2021
Death, Safety, Neurology, Technology, University, Ischemia, Ischemia-reperfusion injury of the appendicular musculoskeletal system, Dean, Rankine scale, Disease, Industry, Hospital of the University of Pennsylvania, Patient, NASDAQ, Brain, Oxygen, Stroke, Terminology, SEC, Chairperson, University of Texas at Austin, Disability, Reperfusion injury, Hospital, Forward-looking statement, Hypoxia, Risk, Reperfusion, True owl, Trial of the century, CEO, Inflammation, Antibody, Program, Dell Medical School, Hope, GLOBE, Prevalence, Stanford University Medical Center, Physician, Blood, Medical imaging, Pharmaceutical industry, Vaccine

XBiotechs new candidate therapy is intended to reduce brain injury that occurs due to ischemia and reperfusion injury.

Key Points: 
  • XBiotechs new candidate therapy is intended to reduce brain injury that occurs due to ischemia and reperfusion injury.
  • Stroke is the leading cause of death and disability in the world todayand the prevalence of stroke is increasing.
  • XBiotechs candidate therapy precisely targets the inflammation process that is believed to result in stroke-related brain injury.
  • This novel drug candidate is the product of a remarkable group of researchers and technicians at XBiotech who work tirelessly to discover potentially revolutionizing medicines.

Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Model

Retrieved on: 
Wednesday, September 29, 2021
Retina, Optic nerve, NCX, Risk, Euronext Paris, 470, Glaucoma, Ischemia, Rabbit, Patient, Ischemia-reperfusion injury of the appendicular musculoskeletal system, Ocular hypertension, Severe cognitive impairment, COX, IOP, Ophthalmic artery, Erosion (morphology), Telescopic sight

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1).

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1).
  • The exploratory nonclinical studies reported today investigated the potential protective effects of NCX 470 on the retina and the optic nerve head.
  • Nonclinical experiments were performed to determine the effect of NCX 470 on ocular vascular reactivity and retinal function after repeated topical ocular dosing in a well-defined model of ischemia/reperfusion injury to the optic nerve in rabbits induced by ET-1.
  • Nicoxs lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.